Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Mercer

Showing results (281-290 of 295) with videos related to

Pageof 30
Sort By:
Archives of General Psychiatry|August 1, 1997
The National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Rationale and methodsP Crits-Christoph, L Siqueland, J Blaine, et al.
The Lancet. Global Health|November 15, 2025
Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 studyBirahim Pierre Ndiaye, Lucy Koech, Laina D Mercer, et al.
JCI Insight|October 8, 2024
Identification of RTS,S/AS01 vaccine-induced humoral biomarkers predictive of protection against controlled human malaria infectionRachel L Spreng, Kelly E Seaton, Lin Lin, et al.
Archives of General Psychiatry|June 8, 1999
Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment StudyP Crits-Christoph, L Siqueland, J Blaine, et al.
The Journal of Infectious Diseases|May 29, 2025
Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum-Exposed, Drug-Treated Kenyan AdultsNathanial K Copeland, Lucas Otieno, June Doryne Otieno, et al.
MMWR. Morbidity and Mortality Weekly Report|June 16, 2022
Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021Javier Martin, Cara C Burns, Jaume Jorba, et al.
Vaccine|March 4, 2025
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in BrazilÉrique José Farias Peixoto de Miranda, Rodrigo T Calado, Fernanda Castro Boulos, et al.
Lancet (London, England)|November 17, 2025
Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 studyRobert W Frenck, Abdi Naficy, Jodi Feser, et al.
The Lancet. Infectious Diseases|May 9, 2024
Genotypic analysis of RTS,S/AS01<sub>E</sub> malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trialMichal Juraska, Angela M Early, Li Li, et al.
Medrxiv : the Preprint Server for Health Sciences|December 4, 2023
Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacyMichal Juraska, Angela M Early, Li Li, et al.
Pageof 30

Showing results (281-290 of 295) with videos related to

Sort By:
Pageof 30
Archives of General Psychiatry|August 1, 1997
The National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Rationale and methodsP Crits-Christoph, L Siqueland, J Blaine, et al.
The Lancet. Global Health|November 15, 2025
Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 studyBirahim Pierre Ndiaye, Lucy Koech, Laina D Mercer, et al.
JCI Insight|October 8, 2024
Identification of RTS,S/AS01 vaccine-induced humoral biomarkers predictive of protection against controlled human malaria infectionRachel L Spreng, Kelly E Seaton, Lin Lin, et al.
Archives of General Psychiatry|June 8, 1999
Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment StudyP Crits-Christoph, L Siqueland, J Blaine, et al.
The Journal of Infectious Diseases|May 29, 2025
Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum-Exposed, Drug-Treated Kenyan AdultsNathanial K Copeland, Lucas Otieno, June Doryne Otieno, et al.
MMWR. Morbidity and Mortality Weekly Report|June 16, 2022
Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021Javier Martin, Cara C Burns, Jaume Jorba, et al.
Vaccine|March 4, 2025
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in BrazilÉrique José Farias Peixoto de Miranda, Rodrigo T Calado, Fernanda Castro Boulos, et al.
Lancet (London, England)|November 17, 2025
Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 studyRobert W Frenck, Abdi Naficy, Jodi Feser, et al.
The Lancet. Infectious Diseases|May 9, 2024
Genotypic analysis of RTS,S/AS01<sub>E</sub> malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trialMichal Juraska, Angela M Early, Li Li, et al.
Medrxiv : the Preprint Server for Health Sciences|December 4, 2023
Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacyMichal Juraska, Angela M Early, Li Li, et al.
Pageof 30